Europe Erythropoietin Drugs Market Research Report - Segmented By Product, Application, Drug Class & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends, & Forecasts (2022 to 2027)
Europe Erythropoietin Drugs Market Size & Growth (2022 to 2027):
As per the research report, the size of the Europe Erythropoietin Drugs Market was valued at USD 3.71 billion in 2022 and estimated to be growing at a CAGR of 9.5%, to reach USD 5.84 billion by 2027 during the forecast period 2022 to 2027.
The increased prevalence of chronic diseases such as CKD and cancer, both of which induce anemia, is a significant growth driver for this market.
The rise in demand for EPO medications is primarily due to cancer, End-Stage Renal Disease, and HIV. Approximately 20% of cancer/HIV patients and 70% of End-Stage Renal Disease patients get chemotherapy, which causes anemia in these patients, necessitating EPO treatment. Therefore, it is the primary source of revenue for the erythropoietin market.
Anemia is a significant driver of erythropoietin production. It is seen in the majority of cancer patients undergoing treatment. The type of chemotherapy required, the type and stage of tumor formations, and the patient's physiological characteristics influence the severity of a patient's sickness.
Severe anemia can induce weariness, weakness, and sadness in cancer patients, especially in youngsters and the elderly, lowering their quality of life. Drugs containing erythropoietin are the most effective treatment for anemia. As a result, the erythropoietin market is predicted to expand over the forecast period.
The Erythropoietin Drug Industry is a vital market driver since it is prescribed for chronic renal failure, chemotherapy, and HIV. In addition, these can also use in pharmaceutical drugs to treat low red blood cell counts during major surgical procedures.
The overwhelming demand for EPO medications is primarily due to rising cancer rates, End-Stage Renal Disease (ESRD), and HIV. Approximately 20% of cancer/HIV patients and 70% of ESRD patients get chemotherapy, which causes anemia in these patients, necessitating EPO medication. Despite this, market restrictions exist because of the high cost of EPO medications, which results in low uptake.
Another factor limiting the growth of the erythropoietin medicines market is the side effects of EPO, such as arterial hypertension, iron deficiency, and influenza-like illness, as well as the extended length of EPO treatment. The rising number of people undergoing surgery is expected to boost the market growth. People who are having surgery are at a high risk of acquiring thrombosis. It induces erythropoiesis by interacting with the erythropoietin receptor on progenitor cells in the bone marrow in a distinct way, allowing for stable and long-term anemia control.
This research report on the Europe Erythropoietin Drugs Market has been segmented and sub-segmented into the following categories:
By Product:
- Epoetin-alpha
- Epoetin-beta
- Darbepoetin-alfa
- Others
By Application:
- Cancer
- Haematology
- Renal Diseases
- Neurology
By Drug Class:
- Biologics
- Biosimilar
By Country:
- UK
- France
- Spain
- Germany
- Italy
- Russia
- Sweden
- Denmark
- Switzerland
- Netherlands
- Turkey
- Czech Republic
- Rest of Europe
Geographically, the Europe is the second-largest contributor. The European erythropoietin Drug market is fiercely competitive with various worldwide and local marketplaces. Market competitiveness is intensified by product diversity, revenue growth, and opportunity.
During major surgical procedures, these can also use pharmaceutical drugs to treat low red blood cell counts. Epoetin alfa is human erythropoietin manufactured in cell culture using recombinant DNA technology. Epoetin alfa is prescribed to treat anemia in persons with renal disease in Europe, particularly in Germany and the United Kingdom.
A significant number of businesses are involved in the development of erythropoietin drugs. Biosimilars with improved efficacy, therapeutic impact, and cost-effectiveness are increasingly introduced. Innovative compounds are generating a growing amount of research and development. Several firms in Germany are working on finding new therapeutic areas for existing medications.
The European erythropoietin Drug market is intensely competitive, with multiple global and local marketplaces. Increased market competitiveness is fueled by product diversity, revenue growth, and opportunity.
KEY MARKET PLAYERS
Key players operating in the Europe Erythropoietin Drugs Market profiled in this report are Johnson & Johnson, Celltrion, Inc, Teva Pharmaceutical Industries Ltd. , Sun Pharmaceutical Industries Ltd. , Dr. Reddy’s Laboratories Ltd.Amgen, Inc. , F. Hoffmann-La Roche Ltd. , LG Life Sciences Ltd. , Biocon Limited and Intas Pharmaceuticals Ltd.,
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Epoetin-alfa
5.1.3 Epoetin-beta
5.1.4 Darbepoetin-alfa
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 Application
5.2.1 Introduction
5.2.2 Cancer
5.2.3 Hematology
5.2.4 Renal diseases
5.2.5 Y-o-Y Growth Analysis, By application
5.2.6 Market Attractiveness Analysis, By application
5.2.7 Market Share Analysis, By application
5.3 Drug class
5.3.1 Introduction
5.3.2 Biologics
5.3.3 Biosimilars
5.3.4 Y-o-Y Growth Analysis, By drug class
5.3.5 Market Attractiveness Analysis, By drug class
5.3.6 Market Share Analysis, By drug class
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By application
6.1.3.4 By drug class
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By application
6.1.4.4 By drug class
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By application
6.1.5.4 By drug class
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Johnson & Johnson
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Celltrion, Inc.
8.3 Teva Pharmaceutical Industries Ltd.
8.4 Amgen, Inc.
8.5 F. Hoffmann-La Roche Ltd.
8.6 LG Life Sciences Ltd.
8.7 Biocon Limited
8.8 Intas Pharmaceuticals Ltd.
8.9 Sun Pharmaceutical Industries Ltd.
8.10 Dr. Reddy’s Laboratories Ltd.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
- Europe Erythropoeitin Drugs Market By Product, From 2022 - 2027 ( USD Billion )
- Europe Epoetin-alfa Market By Region, From 2022 - 2027 ( USD Billion )
- Europe Epoetin-beta Market By Region, From 2022 - 2027 ( USD Billion )
- Europe Darbepoetin-alfa Market By Region, From 2022 - 2027 ( USD Billion )
- Europe Erythropoeitin Drugs Market By Application, From 2022 - 2027 ( USD Billion )
- Europe Cancer Market By Region, From 2022 - 2027 ( USD Billion )
- Europe Hematology Market By Region, From 2022 - 2027 ( USD Billion )
- Europe Renal diseases Market By Region, From 2022 - 2027 ( USD Billion )
- Europe Neurology Market By Region, From 2022 - 2027 ( USD Billion )
- Europe Erythropoeitin Drugs Market By Drug class, From 2022 - 2027 ( USD Billion )
- Europe Biologics Market By Region, From 2022 - 2027 ( USD Billion )
- Europe Biosimilars Market By Region, From 2022 - 2027 ( USD Billion )
- U.K. Erythropoeitin Drugs Market By Product, From 2022 - 2027 ( USD Billion )
- U.K. Erythropoeitin Drugs Market By Application, From 2022 - 2027 ( USD Billion )
- U.K. Erythropoeitin Drugs Market By Drug class, From 2022 - 2027 ( USD Billion )
- Germany Erythropoeitin Drugs Market By Product, From 2022 - 2027 ( USD Billion )
- Germany Erythropoeitin Drugs Market By Application, From 2022 - 2027 ( USD Billion )
- Germany Erythropoeitin Drugs Market By Drug class, From 2022 - 2027 ( USD Billion )
- France Erythropoeitin Drugs Market By Product, From 2022 - 2027 ( USD Billion )
- France Erythropoeitin Drugs Market By Application, From 2022 - 2027 ( USD Billion )
- France Erythropoeitin Drugs Market By Drug class, From 2022 - 2027 ( USD Billion )
- Italy Erythropoeitin Drugs Market By Product, From 2022 - 2027 ( USD Billion )
- Italy Erythropoeitin Drugs Market By Application, From 2022 - 2027 ( USD Billion )
- Italy Erythropoeitin Drugs Market By Drug class, From 2022 - 2027 ( USD Billion )
- Spain Erythropoeitin Drugs Market By Product, From 2022 - 2027 ( USD Billion )
- Spain Erythropoeitin Drugs Market By Application, From 2022 - 2027 ( USD Billion )
- Spain Erythropoeitin Drugs Market By Drug class, From 2022 - 2027 ( USD Billion )
Related Reports
ASK FOR CUSTOMIZATION
Talk to our analyst and get customised report done according to your research needs
INQUIRE FOR DISCOUNT
Check if you can avail any discount. Submit your details and our team will get back to you.
DOWNLOAD FREE SAMPLE
Request to avail a free sample report that reflects this market and its growth.
